Name : Human TROP-2/TACSTD2 Protein
Product Source :
Recombinant Human TROP-2/TACSTD2 Protein is expressed from HEK293 with His tag at the C-Terminus. It contains His27-Thr274.[Accession | P09758]
Molecular Weight :
The protein has a predicted MW of 28.9 kDa. Due to glycosylation, the protein migrates to 40-60 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 95% as determined by HPLC
Formulation :
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3-6 months after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Human TROP-2 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of Human TROP-2 is greater than 95% as determined by SEC-HPLC. ELISA Data Immobilized Human TROP-2, His Tag at 0.5μg/ml (100μl/Well). Dose response curve for Anti-TROP-2 Antibody, hFc Tag with the EC50 of 7.1ng/ml determined by ELISA (QC Test). Batch to Batch Consistency Immobilized Human TROP-2, His Tag at 0.5μg/ml (100μl/Well). Dose response curve for Anti-TROP-2 Antibody, hFc Tag with the EC50 of 7.1ng/ml / 7.2ng/ml / 7.2ng/ml determined by ELISA.
Background :
Trop-2,also known as epithelial glycoprotein-1 antigen (EGP-1),is a protein that in humans is encoded by the TACSTD2 gene.Mutations of this gene result in gelatinous drop-like corneal dystrophy, an autosomal recessive disorder characterized by severe corneal amyloidosis leading to blindness.
Synonyms :
EGP1; EGP-1; TROP2; GA733-1; gp50; T16; TACSTD2; TROP-2; M1S1; TACD2
References & Citations :
(1)Goldenberg D M , Cardillo T M , Govindan S V , et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*[J]. Oncotarget, 2015, 6(26).
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
14-3-3 sigma Proteincustom synthesis
EGFL6 ProteinStorage & Stability
Popular categories:
Integrin alpha L beta 2
CCL13